Merck–Isomorphic Labs deal signals pharma's deepening reliance on AI-native design engines for hard oncology targets.
Merck is partnering with Isomorphic Labs—the AI drug-design spinout built on AlphaFold's Nobel-recognized protein-structure technology—to identify small-molecule candidates against an undisclosed oncology target. Isomorphic contributes its proprietary design engine; Merck brings
